Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity

Hiromi Sakaguchi, Ayumi Kodama, Mari Tomonari, Yukie Ando, Mayumi Tabuchi, Hideto To, Ryosuke Araki, Takashi Kitahara, Hitoshi Sasaki, Shigehiro Ohdo, Shun Higuchi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice. The purpose of this study was to clarify in mice whether the toxic death caused by ADR was reduced by administering ADR after DOC injection when the doses and dosing-interval of ADR and DOC were changed. Methods: ADR alone or a combination of ADR and DOC (ADR/DOC group in which both drugs were administered simultaneously or DOC-ADR group in which ADR was administered after DOC injection) was administered every 7 days in mice. Results: When dosing intervals (0-24 h) were changed, there were no differences in survival rate among the 6, 12, and 24-h interval groups, although these groups showed significantly higher survival rate compared with the ADR/DOC group. When the dose of ADR (2.5-15 mg/kg) was changed, the survival rate was higher in all the DOC-ADR groups than the ADR alone groups. When the dose of DOC (3.125-12.5 mg/kg) was changed, DOC caused a dose-dependent reduction in toxic death. Although there was no striking difference in adverse effects between the ADR alone and DOC-ADR groups, the DOC-ADR group showed markedly attenuated increases in CPK-MB activity compared with the ADR alone group. Conclusions: We conclude that pre-administration of DOC may protect against ADR-induced toxic death and cardiotoxicity.

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalBreast Cancer Research and Treatment
Volume109
Issue number3
DOIs
Publication statusPublished - Jun 1 2008

Fingerprint

docetaxel
Doxorubicin
Poisons
Cardiotoxicity
Injections

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sakaguchi, H., Kodama, A., Tomonari, M., Ando, Y., Tabuchi, M., To, H., ... Higuchi, S. (2008). Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Breast Cancer Research and Treatment, 109(3), 443-450. https://doi.org/10.1007/s10549-007-9667-8

Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. / Sakaguchi, Hiromi; Kodama, Ayumi; Tomonari, Mari; Ando, Yukie; Tabuchi, Mayumi; To, Hideto; Araki, Ryosuke; Kitahara, Takashi; Sasaki, Hitoshi; Ohdo, Shigehiro; Higuchi, Shun.

In: Breast Cancer Research and Treatment, Vol. 109, No. 3, 01.06.2008, p. 443-450.

Research output: Contribution to journalArticle

Sakaguchi, H, Kodama, A, Tomonari, M, Ando, Y, Tabuchi, M, To, H, Araki, R, Kitahara, T, Sasaki, H, Ohdo, S & Higuchi, S 2008, 'Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity', Breast Cancer Research and Treatment, vol. 109, no. 3, pp. 443-450. https://doi.org/10.1007/s10549-007-9667-8
Sakaguchi, Hiromi ; Kodama, Ayumi ; Tomonari, Mari ; Ando, Yukie ; Tabuchi, Mayumi ; To, Hideto ; Araki, Ryosuke ; Kitahara, Takashi ; Sasaki, Hitoshi ; Ohdo, Shigehiro ; Higuchi, Shun. / Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. In: Breast Cancer Research and Treatment. 2008 ; Vol. 109, No. 3. pp. 443-450.
@article{d579c3d309ed4d5d956638f36fb6add1,
title = "Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity",
abstract = "Background: We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice. The purpose of this study was to clarify in mice whether the toxic death caused by ADR was reduced by administering ADR after DOC injection when the doses and dosing-interval of ADR and DOC were changed. Methods: ADR alone or a combination of ADR and DOC (ADR/DOC group in which both drugs were administered simultaneously or DOC-ADR group in which ADR was administered after DOC injection) was administered every 7 days in mice. Results: When dosing intervals (0-24 h) were changed, there were no differences in survival rate among the 6, 12, and 24-h interval groups, although these groups showed significantly higher survival rate compared with the ADR/DOC group. When the dose of ADR (2.5-15 mg/kg) was changed, the survival rate was higher in all the DOC-ADR groups than the ADR alone groups. When the dose of DOC (3.125-12.5 mg/kg) was changed, DOC caused a dose-dependent reduction in toxic death. Although there was no striking difference in adverse effects between the ADR alone and DOC-ADR groups, the DOC-ADR group showed markedly attenuated increases in CPK-MB activity compared with the ADR alone group. Conclusions: We conclude that pre-administration of DOC may protect against ADR-induced toxic death and cardiotoxicity.",
author = "Hiromi Sakaguchi and Ayumi Kodama and Mari Tomonari and Yukie Ando and Mayumi Tabuchi and Hideto To and Ryosuke Araki and Takashi Kitahara and Hitoshi Sasaki and Shigehiro Ohdo and Shun Higuchi",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s10549-007-9667-8",
language = "English",
volume = "109",
pages = "443--450",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity

AU - Sakaguchi, Hiromi

AU - Kodama, Ayumi

AU - Tomonari, Mari

AU - Ando, Yukie

AU - Tabuchi, Mayumi

AU - To, Hideto

AU - Araki, Ryosuke

AU - Kitahara, Takashi

AU - Sasaki, Hitoshi

AU - Ohdo, Shigehiro

AU - Higuchi, Shun

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice. The purpose of this study was to clarify in mice whether the toxic death caused by ADR was reduced by administering ADR after DOC injection when the doses and dosing-interval of ADR and DOC were changed. Methods: ADR alone or a combination of ADR and DOC (ADR/DOC group in which both drugs were administered simultaneously or DOC-ADR group in which ADR was administered after DOC injection) was administered every 7 days in mice. Results: When dosing intervals (0-24 h) were changed, there were no differences in survival rate among the 6, 12, and 24-h interval groups, although these groups showed significantly higher survival rate compared with the ADR/DOC group. When the dose of ADR (2.5-15 mg/kg) was changed, the survival rate was higher in all the DOC-ADR groups than the ADR alone groups. When the dose of DOC (3.125-12.5 mg/kg) was changed, DOC caused a dose-dependent reduction in toxic death. Although there was no striking difference in adverse effects between the ADR alone and DOC-ADR groups, the DOC-ADR group showed markedly attenuated increases in CPK-MB activity compared with the ADR alone group. Conclusions: We conclude that pre-administration of DOC may protect against ADR-induced toxic death and cardiotoxicity.

AB - Background: We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice. The purpose of this study was to clarify in mice whether the toxic death caused by ADR was reduced by administering ADR after DOC injection when the doses and dosing-interval of ADR and DOC were changed. Methods: ADR alone or a combination of ADR and DOC (ADR/DOC group in which both drugs were administered simultaneously or DOC-ADR group in which ADR was administered after DOC injection) was administered every 7 days in mice. Results: When dosing intervals (0-24 h) were changed, there were no differences in survival rate among the 6, 12, and 24-h interval groups, although these groups showed significantly higher survival rate compared with the ADR/DOC group. When the dose of ADR (2.5-15 mg/kg) was changed, the survival rate was higher in all the DOC-ADR groups than the ADR alone groups. When the dose of DOC (3.125-12.5 mg/kg) was changed, DOC caused a dose-dependent reduction in toxic death. Although there was no striking difference in adverse effects between the ADR alone and DOC-ADR groups, the DOC-ADR group showed markedly attenuated increases in CPK-MB activity compared with the ADR alone group. Conclusions: We conclude that pre-administration of DOC may protect against ADR-induced toxic death and cardiotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=43749116512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749116512&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9667-8

DO - 10.1007/s10549-007-9667-8

M3 - Article

C2 - 17661173

AN - SCOPUS:43749116512

VL - 109

SP - 443

EP - 450

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -